(Q50565674)

English

Tamoxifen in high-risk premenopausal women with primary breast cancer receiving adjuvant chemotherapy. Report from the Danish Breast Cancer co-operative Group DBCG 82B Trial.

scientific article published in November 1999

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

15 March 2018

http://europepmc.org/abstract/MED/10674010

Tamoxifen in high-risk premenopausal women with primary breast cancer receiving adjuvant chemotherapy. Report from the Danish Breast Cancer co-operative Group DBCG 82B Trial. (English)

1 reference

Europe PubMed Central

PubMed publication ID

15 March 2018

http://europepmc.org/abstract/MED/10674010

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Andersson M

1

1 reference

Europe PubMed Central

PubMed publication ID

15 March 2018

http://europepmc.org/abstract/MED/10674010

Kamby C

2

1 reference

Europe PubMed Central

PubMed publication ID

15 March 2018

http://europepmc.org/abstract/MED/10674010

Jensen MB

3

1 reference

Europe PubMed Central

PubMed publication ID

15 March 2018

http://europepmc.org/abstract/MED/10674010

Mouridsen H

4

1 reference

Europe PubMed Central

PubMed publication ID

15 March 2018

http://europepmc.org/abstract/MED/10674010

Ejlertsen B

5

1 reference

Europe PubMed Central

PubMed publication ID

15 March 2018

http://europepmc.org/abstract/MED/10674010

Dombernowsky P

6

1 reference

Europe PubMed Central

PubMed publication ID

15 March 2018

http://europepmc.org/abstract/MED/10674010

Rose C

7

1 reference

Europe PubMed Central

PubMed publication ID

15 March 2018

http://europepmc.org/abstract/MED/10674010

Cold S

8

1 reference

Europe PubMed Central

PubMed publication ID

15 March 2018

http://europepmc.org/abstract/MED/10674010

Overgaard M

9

1 reference

Europe PubMed Central

PubMed publication ID

15 March 2018

http://europepmc.org/abstract/MED/10674010

Andersen J

10

1 reference

Europe PubMed Central

PubMed publication ID

15 March 2018

http://europepmc.org/abstract/MED/10674010

Kjaer M

11

1 reference

Europe PubMed Central

PubMed publication ID

15 March 2018

http://europepmc.org/abstract/MED/10674010

publication date

1 November 1999

1 reference

Europe PubMed Central

PubMed publication ID

15 March 2018

http://europepmc.org/abstract/MED/10674010

European Journal of Cancer

1 reference

Europe PubMed Central

PubMed publication ID

15 March 2018

http://europepmc.org/abstract/MED/10674010

35

1 reference

Europe PubMed Central

PubMed publication ID

15 March 2018

http://europepmc.org/abstract/MED/10674010

12

1 reference

Europe PubMed Central

PubMed publication ID

15 March 2018

http://europepmc.org/abstract/MED/10674010

1659-1666

1 reference

Europe PubMed Central

PubMed publication ID

15 March 2018

http://europepmc.org/abstract/MED/10674010

Adjuvant chemotherapy with cyclophosphamide or CMF in premenopausal women with stage II breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900141-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Evidence of a castration-mediated effect of adjuvant cytotoxic chemotherapy in premenopausal breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900141-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Chemotherapy versus combination of chemotherapy and endocrine therapy in advanced breast cancer: A prospective randomized study

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900141-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Chemotherapy with or without tamoxifen in postmenopausal patients with late breast cancer. A randomized study

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900141-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Combined cytotoxic and endocrine therapy in postmenopausal patients with advanced breast cancer. A randomized study of CMF vs CMF plus tamoxifen

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900141-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. Danish Breast Cancer Cooperative Group 82b Trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900141-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Danish Breast Cancer Cooperative Group (DBCG). A description of the register of the nation-wide programme for primary breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900141-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Histological grading and prognosis in breast cancer; a study of 1409 cases of which 359 have been followed for 15 years

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900141-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Quality control of end results in a Danish adjuvant breast cancer multi-center study.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900141-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900141-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900141-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized trial of two versus five years of adjuvant tamoxifen for postmenopausal early stage breast cancer. Swedish Breast Cancer Cooperative Group

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900141-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Multimodal therapy with CMF in resectable breast cancer with positive axillary nodes: the Milan Institute experience

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900141-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Ten-year experience with CMF-based adjuvant chemotherapy in resectable breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900141-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Cyclophosphamide, methotrexate, and fluorouracil with and without doxorubicin in the adjuvant treatment of resectable breast cancer with one to three positive axillary nodes

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900141-0

7 January 2021

based on heuristic

inferred from DOI database lookup

"Classical" CMF versus a 3-weekly intravenous CMF schedule in postmenopausal patients with advanced breast cancer. An EORTC Breast Cancer Co-operative Group Phase III Trial (10808)

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900141-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Adding adjuvant CMF chemotherapy to either radiotherapy or tamoxifen: are all CMFs alike? The International Breast Cancer Study Group (IBCSG).

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900141-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Beneficial effect of adjuvant tamoxifen therapy in primary breast cancer patients with high oestrogen receptor values

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900141-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized trial to evaluate the addition of tamoxifen to cyclophosphamide, 5-fluorouracil, prednisone adjuvant therapy in premenopausal women with node-positive breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900141-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Adjuvant chemotherapy with and without tamoxifen in the treatment of primary breast cancer: 5-year results from the National Surgical Adjuvant Breast and Bowel Project Trial

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900141-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Adjuvant trial for stage II receptor-positive breast cancer: CMF vs. CMF + tamoxifen in a single centre

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900141-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Adjuvant randomized trials of doxorubicin/cyclophosphamide versus doxorubicin/cyclophosphamide/tamoxifen and CMF chemotherapy versus tamoxifen in women with node-positive breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900141-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Chemotherapy versus tamoxifen versus chemotherapy plus tamoxifen in node-positive, oestrogen-receptor positive breast cancer patients. An update at 7 years of the 1st GROCTA (Breast Cancer Adjuvant Chemo-Hormone Therapy Cooperative Group) trial

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900141-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Antagonism of chemotherapy-induced cytotoxicity for human breast cancer cells by antiestrogens

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900141-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Effectiveness of adjuvant chemotherapy in combination with tamoxifen for node-positive postmenopausal breast cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900141-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Prognostic role of amenorrhea induced by adjuvant chemotherapy in premenopausal patients with early breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900141-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Prognostic impact of amenorrhoea after adjuvant chemotherapy in premenopausal breast cancer patients with axillary node involvement: results of the International Breast Cancer Study Group (IBCSG) Trial VI.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900141-0

7 January 2021

based on heuristic

inferred from DOI database lookup

1-phenylalanine mustard (L-PAM) in the management of premenopausal patients with primary breast cancer: lack of association of disease-free survival with depression of ovarian function. National Surgical Adjuvant Project for Breast and Bowel Cancers

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900141-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. The Cancer and Leukemia Group B

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900141-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0959-8049(99)00141-0

1 reference

Europe PubMed Central

PubMed publication ID

15 March 2018

http://europepmc.org/abstract/MED/10674010

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

15 March 2018

http://europepmc.org/abstract/MED/10674010

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q50565674&oldid=1962322793"